Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US

Ken O'Day,1 Krithika Rajagopalan,2 Kellie Meyer,1 Andrei Pikalov,2 Antony Loebel21Xcenda, Palm Harbor, FL, 2Sunovion Pharmaceuticals, Marlborough, MA, USABackground: The purpose of this study was to evaluate the long-term cost-effectiveness (including hospitalizations and cardiometabolic con...

Full description

Bibliographic Details
Main Authors: O'Day K, Rajagopalan K, Meyer K, Pikalov A, Loebel A
Format: Article
Language:English
Published: Dove Medical Press 2013-09-01
Series:ClinicoEconomics and Outcomes Research
Online Access:http://www.dovepress.com/long-term-cost-effectiveness-of-atypical-antipsychotics-in-the-treatme-a14326